The significant strength of this study is its population-based design; however, because individuals were recruited from cancer registries rather than clinical settings, we do not have detailed clinical information about features that could possibly accompany the genetic syndromes and assist variant classification, especially for variants identified in FLCN, FH, and TSC1. Here, FH is linked to cancer.